ArticleNature communications2018
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- The convergent roles of metabolic dysfunction, alcohol, and iron in steatotic liver disease: a review.Bioscience reports · 2026Review
- Hepatocyte iron suppresses liver fibrosis via fibrolytic neutrophil recruitment in cholestasis.JHEP reports : innovation in hepatology · 2025Article
- Targeting the Liver Serine Protease TMPRSS6 Ameliorates Steatosis and Attenuates Fibrosis in Experimental MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Assessing the effects of menopause and obesity on matriptase-2 and neurokinin B concentrations: A cross-sectional study.Journal of medical biochemistry · 2025Article
- Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications.Cell biochemistry and biophysics · 2025Review
- Current Landscape of Hepcidin Therapeutics.Advances in experimental medicine and biology · 2025Review
- Article
- Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease.Frontiers in pharmacology · 2025Review
- Iron homeostasis and insulin sensitivity: unraveling the complex interactions.Reviews in endocrine & metabolic disorders · 2024Review
- Targeting cell death in NAFLD: mechanisms and targeted therapies.Cell death discovery · 2024Review
- Transferrin receptor levels and its rare variant are associated with human obesity.Journal of diabetes · 2024Article
- Mechanisms of ferroptosis in nonalcoholic fatty liver disease and therapeutic effects of traditional Chinese medicine: a review.Frontiers in medicine · 2024Review
- Hepcidin deficiency in mice impairs white adipose tissue browning possibly due to a defect in de novo adipogenesis.Scientific reports · 2023Article
- Type II Transmembrane Serine Proteases as Modulators in Adipose Tissue Phenotype and Function.Biomedicines · 2023Review
- The Gut Microbiome and Ferroptosis in MAFLD.Journal of clinical and translational hepatology · 2023Review
- Article
- Ferroptosis in non-alcoholic liver disease: Molecular mechanisms and therapeutic implications.Frontiers in nutrition · 2023Review
- Iron-tracking strategies: Chaperones capture iron in the cytosolic labile iron pool.Frontiers in molecular biosciences · 2023Review
- Ferroptosis: Shedding Light on Mechanisms and Therapeutic Opportunities in Liver Diseases.Cells · 2022Review
- Iron Homeostasis and Energy Metabolism in Obesity.Clinical nutrition research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations in iron status have frequently been associated with obesity and other metabolic disorders. The hormone hepcidin stands out as a key regulator in the maintenance of iron homeostasis by controlling the main iron exporter, ferroportin. Here we demonstrate that the deficiency in the hepcidin repressor matriptase-2 (Tmprss6) protects from high-fat diet-induced obesity. Tmprss6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.